Telix Pharmaceuticals Ltd has released a press release.
ProstACT TARGET Phase II Study Ethics Approval
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix Enters Licence Agreement with Lilly for Olaratumab
- Telix, GMS & Monash Awarded $23 million Federal Funding
- Commercial Launch - Illuccix Now Available to Order in US
- FDA Orphan Drug Designation for Bone Marrow Conditioning
- Telix and Xiel Sign U.K. and Ireland Distribution Agreement
Later from Telix Pharmaceuticals
- Appendix 4C and Activities Report for March 2022 quarter
- Illuccix Reimbursement Milestone and Launch Updates
- Leadership changes including Darren Smith appointment as CFO
- Telix receives AUD$17.25 million R&D tax refund
- Expansion of Partnership with RefleXion for Prostate Cancer
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals